Organon Return on Equity

Organon (OGN) currently reports a ROE of 8.81%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore Organon's ROE history and peer comparisons.

Organon's ROE of 8.81% is lower than the Healthcare sector average of 13.26%. That is roughly 33.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Organon's current 8.81% should be judged against Healthcare norms (sector average: 13.26%) and against OGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 8.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Organon, and consider following OGN for alerts when major investors trade the stock.

Organon is classified in the Healthcare sector. On ROE, it currently shows 8.81% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OGN with unrelated industries.